Auranofin inhibits interleukin-1β-induced transcript of cyclooxygenase-2 on cultured human synoviocytes

European Journal of Pharmacology

Volumn 385, Issue 1, 1999, Pages 71-79

  Yamada, Ryoji ^a   Sano, Hajime ^a   Hla, Timothy ^b   Hashiramoto, Akira ^a   Fukui, Wakako ^a   Miyazaki, Satoshi ^a   Kohno, Masataka ^a   Tsubouchi, Yasunori ^a   Kusaka, Yoshiaki ^a   Kondo, Motoharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Auranofin; Cyclooxygenase 2; Nuclear factor B; Prostaglandin E2; Synovial fibroblast like cell

Indexed keywords

AURANOFIN; CYCLOOXYGENASE 2; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; PROSTAGLANDIN E2;

ADULT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; NORTHERN BLOTTING; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; SYNOVIOCYTE; WESTERN BLOTTING;

AURANOFIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL SURVIVAL; CELLS, CULTURED; CHROMIUM RADIOISOTOPES; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEXAMETHASONE; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTERLEUKIN-1; ISOENZYMES; MEMBRANE PROTEINS; NF-KAPPA B; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RNA, MESSENGER; SYNOVIAL MEMBRANE; TRANSCRIPTION, GENETIC;

EID: 0032762976     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00707-4     Document Type: Article

References (57)

1. Appleby S.B., Ristimaki A., Neilson K., Narko K., Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem. J. 302:1994;723-727.
2. Arend W.P., Dayer J.-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 33:1990;305-315.
3. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., Healey L.A., Kaplan S.R. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
4. Baeuerle P.A. The inducible transcription activator NF-κ B: regulation by distinct protein subunits. Biochim. Biophys. Acta. 1072:1991;63-80.
5. Beg A.A., Finco T.S., Nantermet P.V., Baldwin A.S. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I κ B α: a mechanism for NF-κ B activation. Mol. Cell. Biol. 13:1993;3301-3310.
6. Ben-Av P., Crofford L.J., Wilder R.L., Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372:1995;83-87.
7. Bondeson J., Sundler R. Antirheumatic gold compounds and penicillamine enhance protein kinase C-mediated activation of the arachidonate-mobilizing phospholipase A2 in mouse macrophages. J. Leukocyte Biol. 54:1993;329-335.
8. Bondeson J., Sundler R. Auranofin inhibits the induction of interleukin 1β and tumor necrosis factor α mRNA in macrophages. Biochem. Pharmacol. 50:1995;1753-1759.
9. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
10. Crofford L.J. COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. 24(Suppl. 49):1997;15-19.
11. Crofford L.J., Wilder R.L., Ristimaki A.P., Sano H., Remmers E.F., Epps H.R., Hla T. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. J. Clin. Invest. 93:1994;1095-1101.
12. Crofford L.J., Tan B., McCarthy C.J., Hla T. Involvement of nuclear factor κ B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum. 40:1997;226-236.
13. Daniel L.W., Civoli F., Rogers M.A., Smitherman P.K., Raju P.A., Roederer M. ET-18-ECH3 inhibits nuclear factor-κ B activation by 12-O-tetradecanoylphorbol-13-acetate but not by tumor necrosis factor-α or interleukin 1 α Cancer Res. 55:1995;4844-4849.
14. Davis P., Johnston C., Miller C.L., Wong K. Effects of gold compounds of the function of phagocytic cells. Arthritis Rheum. 26:1983;82-86.
15. Dimartino M.J., Waltz D.T. Inhibition of lysosomal enzyme release from rat leukocytes by auranofin. Inflammation. 2:1977;131-142.
16. Elmgreen J., Ronne A., Nielsen O. Inhibition of human neutrophils by auranofin: chemotaxis and metabolism of arachidonate via the 5-lipoxygenase pathway. Ann. Rheum. Dis. 48:1989;134-138.
17. Firestein G.S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum. 39:1996;1781-1790.
18. Froscio M., Murray A.W., Hurst N.P. Inhibition of protein kinase C activity by the antirheumatic drug auranofin. Biochem. Pharmacol. 38:1989;2087-2089.
19. Furst D.E. Meloxicam: selective COX-2 inhibition in clinical practice. Semin. Arthritis Rheum. 26(Suppl. 1):1997;21-27.
20. Gottlieb N.L. Comparative pharmacokinetics of parenteral and oral gold compounds. J. Rheumatol. 9:1982;99-109.
21. Hall T.J., Jeker H., Nyugen H., Schaeublin M. Gold salts inhibit osteoclastic bone resorption in vitro. Inflammation Res. 45:1996;230-233.
22. Harris E.D. Rheumatoid arthritis: pathophysiology and implications for therapy. N. Engl. J. Med. 322:1990;1277-1289.
23. Hashimoto K., Whitehurst C.E., Matsubara T., Hirohata K., Lipsky P.E. Immunomodulatory effects of therapeutic gold compounds. J. Clin. Invest. 89:1992;1839-1848.
24. Hashimoto K., Whitehurst C.E., Lipsky P.E. Synergistic inhibition of T cell proliferation by gold sodium thiomalate and auranofin. J. Rheumatol. 21:1994;1020-1026.
25. Hashiramoto A., Sano H., Maekawa T., Kawahito Y., Kimura S., Kusaka Y., Wilder R.L., Kato H., Kondo M., Nakajima H. C-myc antisense oligodeoxynucleotides can induce apoptosis and downregulates Fas expression in rheumatoid synoviocytes. Arthritis Rheum. 42:1999;954-962.
26. Hirohata S. Inhibition of human B cell activation by gold compounds. Clin. Immunol. Immunopathol. 81:1996;175-181.
27. Hla T., Neilson K. Human cyclooxygenase 2 cDNA. Proc. Natl. Acad. Sci. U. S. A. 89:1992;7384-7388.
28. Imamura F., Aono H., Hasunuma T., Sumida T., Tateishi H., Maruo S., Nishioka K. Monoclonal expansion of synoviocytes in rheumatoid arthritis. Arthritis Rheum. 41:1998;1979-1986.
29. Kean W.F., Lock C.J.L., Howard-Lock H. Gold complex research in medical science. Difficulties with experimental design. Inflammopharmacology. 1:1991;103-114.
30. Klaushofer K., Hoffmann O., Horandner H., Karasegh S., Fratzl-Zelman N., Leis H.-J., Gleispach H., Koller K., Peterlik M. Effect of auranofin on resorption, prostaglandin synthesis and ultrastructure of bone cells in cultured mouse calvaria. J. Rheumatol. 16:1989;749-756.
31. Lipsky P.E., Isakson P.C. Outcome of specific COX-2 inhibition in rheumatoid arthritis. J. Rheumatol. 24(Suppl. 49):1997;9-14.
32. Lipsky P.E., Ziff M. Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds. J. Clin. Invest. 59:1977;455-466.
33. Macchia L., Paola R.D., Guerrese M.C., Chiechi L.M., Tursi A., Caiaffa M.F., Haeggstrom J.Z. Expression of prostaglandin endoperoxide H synthase 1 and 2 in human placenta at term. Biophys. Biochem. Res. Commun. 233:1997;496-501.
34. Mahoney C.W., Hensey C.E., Azzi A. Auranofin, gold thiomalate, and gold thioglucose inhibit protein kinase C. Biochem. Pharmacol. 38:1989;3383-3386.
35. Matsubara T., Saegusa Y., Hirohata K. Low dose compounds inhibit fibroblast proliferation and do not affect interleukin-1 secretion by macrophages. Arthritis Rheum. 31:1988;1272-1280.
36. Niiro H., Otsuka T., Izuhara K., Yamaoka K., Ohshima K., Tanabe T., Hara S., Nemoto Y., Tanaka Y., Nakashima H., Niho Y. Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils. Blood. 89:1997;1621-1628.
37. Parente J.E., Walsh M.P., Girard P.R., Kuo J.F., Ng D.S., Wong K. Effects of gold coordination complexes on neutrophil function are mediated via inhibition of protein kinase C. Mol. Pharmacol. 35:1989;26-33.
38. Peters-Golden M., Shelly C. The oral gold compound auranofin triggers arachidonate release and cyclooxygenase metabolism in the alveolar macrophage. Prostaglandins. 36:1988;773-786.
39. Qu Z., Garcia C.H., O'rourke L.M., Planck S.R., Kohli M., Rosenbaum J.T. Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Arthritis Rheum. 37:1994;212-220.
40. Robinson D.R., Tashjian A.H., Levine L. Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis. J. Clin. Invest. 56:1975;1181-1188.
41. 2 formation. J. Biol. Chem. 271:1996;31496-31501.
42. Sano H., Hla T., Maier J.A.M., Crofford L.J., Case J.P., Maciag T., Wilder R.L. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjutant and streptococcal cell wall arthritis. J. Clin. Invest. 89:1992;97-108.
43. Scheinberg M.A., Santos L.A.M.B., Finkelstein A.E. The effect of auranofin and sodium aurothiomalate on peripheral blood monocytes. J. Rheumatol. 9:1982;366-369.
44. Seitz M., Loetscher P., Dewald B., Towbin H., Baggiolini M. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs. J. Rheumatol. 24:1997;1471-1476.
45. Siegle I., Klein T., Backman J.T., Saal J.G., Nusing R.M., Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue. Arthritis Rheum. 41:1998;122-129.
46. Smith W.L., Meade E.A., Dewitt D.L. Pharmacology of prostaglandin endoperoxide synthase isozymes-1 and -2. Ann. N. Y. Acad. Sci. 714:1994;136-142.
47. 2 production. Arthritis Rheum. 41:1998;130-138.
48. Tett S.E. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin. Pharmacokinet. 25:1993;392-407.
49. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (London), New Biol. 231:1971;232-235.
50. Vane J.R., Bakhle Y.S., Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38:1998;97-120.
51. Vergne P., Liagre B., Bertin P., Cook-Moreau J., Treves R., Beneytout J.L., Rigaud M. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. J. Rheumatol. 25:1998;433-440.
52. William D.H., Jeffery L.J., Murray E.J. Aurothioglucose inhibits induced NF-κ B and AP-1 activity by acting as an IL-1 functional antagonist. Biochim. Biophys. Acta. 1180:1992;9-14.
53. Wong K., Parente J., Prasad K.V.S., Ng D. Auranofin modulated cytoplasmic free calcium in neutrophils by mobilizing intracellular calcium and inhibiting protein kinase C. J. Biol. Chem. 265:1990;21454-21461.
54. 2 production dependent upon cyclooxygenase-1 and cyclooxygenase-2 and its contradictory modulation by auranofin in rat peritoneal macrophages. J. Pharmacol. Exp. Ther. 281:1997;1005-1012.
55. 2 production by rat peritoneal macrophages. Eur. J. Pharmacol. 325:1997;221-227.
56. Yang J.-P., Merin J.P., Nakano T., Kato T., Kitade Y., Okamoto T. Inhibition of DNA-binding activity of NF-κ B by gold compounds in vitro. FEBS Lett. 361:1995;89-96.
57. Yanni G., Farahat M.N.M.R., Poston R.N., Panayi G.S. Intramuscular gold decreases cytokine expression and macrophage numbers in the rheumatoid synovial membrane. Ann. Rheum. Dis. 53:1994;315-322.